Reuters |
AstraZeneca makes small front-end bet on potential asthma drug
Philly.com (blog) Having fended off Pfizer – for now, at least – AstraZeneca struck a much smaller deal to license a potential asthma drug being developed by Synairgen. AstraZeneca is based in the United Kingdom – London for now, but moving the headquarters to Cambridge … AstraZeneca builds pipeline with $232 million Synairgen asthma deal AstraZeneca licenses IFN-beta therapy for viral-induced asthma exacerbation AstraZeneca extends global shopping spree with $232M asthma drug deal |
View full post on asthma – Google News